Skip to main content

Schroders Capital — Portfolio, Page 2

Investor actively backing innovative startups and growth-stage companies across various industries and funding rounds.

40
Companies
$6.4B
Total invested
$152.7M
Avg. check
27
Industries
Biotechnology 10Therapeutics 8Health Care 7Medical 5Biopharma 3Life Science 3+21 more
Founder contacts

Verified emails & LinkedIn for founders across this portfolio.

jane@on●●●●●●●.com
linkedin.com/in/●●●●●●
Verified contacts, updated monthly
Get instant access →

Portfolio companies

Showing 2540 of 40
Vantage Data Centers
January 2026

Vantage Data Centers designs and develops data center campuses to large cloud providers, AI enterprises, and other tech-driven businesses.

Data Center · Denver$341.0M Debt Financing
Kinaset Therapeutics
January 2026

Kinaset Therapeutics is a biopharma company that focuses on advancement of novel drugs in areas of unmet medical needs.

Health Care · Boston$103.0M Series B
AgroStar
November 2025

AgroStar is an agritech company that offers agribusiness farming, rural e-commerce and retail services.

Agriculture · Pune$30.0M Series Unknown
Artios Pharma
November 2025

Artios Pharma is a biopharmaceutical company that provides new solutions in the DNA damage response (DDR) field.

Biopharma · Cambridge$115.0M Series D
AAVantgarde Bio
November 2025

AAVantgarde Bio is a clinical-stage biotechnology company that develops gene therapies for inherited retinal disorders.

Biotechnology · Milano$141.0M Series B
HAYA Therapeutics
September 2025

HAYA Therapeutics is a biotechnology company developing precision RNA-guided medicines that target the dark genome.

Biotechnology · LausanneGrant
Draig Therapeutics
June 2025

Draig Therapeutics is a clinical-stage biopharmaceutical startup.

Biopharma · Cardiff$140.0M Series A
Azafaros
May 2025

Azafaros aims at developing new therapeutic agents for the treatment of rare metabolic disorders.

Biotechnology · Leiden$147.6M Series B
Eikon Therapeutics
February 2025

Eikon Therapeutics is a biopharmaceutical company that develops live-cell resolution microscopy and engineering for drug discovery.

Biotechnology · Hayward$350.7M Series D
Luminance
February 2025

Luminance provides an AI-powered platform for contract generation, negotiation, and post-execution analysis using legal-focused models.

Artificial Intelligence (AI) · Cambridge$75.0M Series C
Alentis Therapeutics
November 2024

ALENTIS Therapeutics is a Swiss-French biotech company developing novel therapeutics in advanced liver disease and cancer.

Biotechnology · Allschwil$181.4M Series D
Somagenetix
October 2024

Somagenetix is a new firm that wants to be a leader in gene therapy by developing first-in-class treatments for phagocyte-related illnesses.

Pharmaceutical · Zürich$11.7M Series A
Epsilogen
September 2024

Epsilogen is a developer of an immuno-oncology company intended to develop immunoglobulin antibodies to treat cancer.

Biopharma · London$16.3M Series B
Araris Biotech
April 2023

Araris Biotech is a biotechnology company that develops antibody-drug conjugates for efficient payload attachment.

Biotechnology · ZürichGrant
Healthy Workers
April 2022

Healthy Workers makes employee well-being measurable.

Analytics · Amsterdam$1.7M Seed
Ambys Medicines
December 2021

Ambys Medicines is a biotechnology company focused on discovering and developing regenerative and restorative therapies.

Biotechnology · South San Francisco$47.0M Series A

Where Schroders Capital invests

Biotechnology10
Therapeutics8
Health Care7
Medical5
Biopharma3
Life Science3

About Schroders Capital's portfolio

How many companies has Schroders Capital invested in?

Schroders Capital has invested in 40 companies tracked in our database. The portfolio spans multiple industries and funding stages, from seed-stage startups to late-stage companies.

What industries does Schroders Capital invest in?

Schroders Capital's top investment sectors include Biotechnology, Therapeutics, Health Care, Medical, Biopharma. The firm invests across 27 different industry categories.

What is Schroders Capital's largest investment?

Among tracked funding rounds, Eikon Therapeutics received $350.7M in a Series D round. Schroders Capital's total known invested capital is $6.4B.

What is the average investment size for Schroders Capital?

Schroders Capital's average investment size is $152.7M across its portfolio of 40 companies.

What are Schroders Capital's most recent investments?

Recent Schroders Capital portfolio additions include Vantage Data Centers, Kinaset Therapeutics, AgroStar, Artios Pharma, AAVantgarde Bio. These companies were founded in 2020 or later.

Reach the founders behind these 40 companies
Verified emails and LinkedIn profiles, updated monthly.
Get instant access →